MS8511 (hydrochloride) is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC50 values of 100 nM (G9a) and 140 nM (GLP), and Kd values of 44 nM (G9a) and 46 nM (GLP). MS8511 (hydrochloride) reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 (hydrochloride) can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS).

MS7131 is a USP1-recruiting DUBTACs. MS7131 effectively reduces histone H3 lysine 27 trimethylation and significantly suppresses the proliferation and clonogenicity of cancer cells.

MS1262-C3-amide-C10-amine is a E3 Ligase Ligand-Linker Conjugates. MS1262-C3-amide-C10-amine incorporates a GLP ligand for the E3 ligase SPOP, and a PROTAC linker. MS1262-C3-amide-C10-amine can be used to design PROTACs such as MS479.

MS-073 (CP162398) is a P-glycoprotein (P-gp) inhibitor. MS-073 reverses multidrug resistance in drug-resistant cells by competitively inhibiting drug binding to P-glycoprotein.

MRL828 combines a Tau pathology-binding ligand and modified guanine moiety based on the ATTEC technology to selectively designate aggregated tau proteins for clearance via the ALP. MRL828 decreases intracellular Tau aggregates and promotes the secretion of Tau.

MRK-990 is the inhibitor for PRMT that inhibits PRMT5 and PRMT9 with IC50 of 30 nM and 10 nM.

MR44397 is a WD40 repeat (WDR) 5 ligand, can be used for cancer research.

MP-010 is a FKBP12 ligand that regulates cytosolic calcium by stabilizing RyR channel activity. MP-010 promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice, as evidenced by improved motor coordination, increased integrity of neuromuscular junctions, and significantly enhanced survival of spinal motor neurons. MP-010 can be used for research in the field of neurological diseases.

MNN-02-155 is a bivalent molecular glue with with dual binding to p300/CBP and BCL6. MNN-02-155 induces potent activation of the BCL6-target reporter gene and cell death. MNN-02-155 can be used for the study of diffuse large B cell lymphomas (DLBCLs).

MMB-4 is an oxime that can reactivate cholinesterases that have been inactivated by exposure to organophosphates such as Sarin or Soman.

MLS000389544 is a selective and potent methylsulfonylnitrobenzoate thyroid hormone receptor β (TRβ) antagonist that blocks the association of TRβ with steroid receptor coactivator 2 (SRC2).

MI-888 is an orally active MDM2 inhibitor with a Ki of 0.44 nM. MI-888 can inhibit the MDM2-p53 interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity.

MI-883 is the orally active agonist for Constitutive Androstane Receptor (CAR, EC50=73 nM) and the antagonist for Pregnane X Receptor (PXR, IC50=0.1 μM). MI-883 stimulates CAR LBD assembly (EC50=0.38 µM) and CAR3 variant activation (EC50=0.074 µM), induces CYP2B6 mRNA expression in HepaRG and primary human hepatocytes. MI-883 inhibits basal PXR activity IC50=2.03 µM) in transiently transfected HepG2 cells, blocks CYP3A4 mRNA expression in HepG2. MI-883 regulates cholesterol metabolism and bile acid excretion, improves hypercholesterolemia in mouse models.

MI-1063 is an inhibitor for DMD-2, that blocks the MDM2-p53 interaction, and activates the tumor suppressor function of p53. MI-1063 inhibits the growth of cancer cell RS4-11 and MV4-11 with IC50 of 179 nM and 93 nM. MI-1063 can be used as target protein ligand in synthesis of PROTAC degrader MD-265.

MethADP (Adenosine 5'-(α,β-methylene)diphosphate) trisodium is a CD73 inhibitor. MethADP trisodium can be used for the research of ATP-adenosine pathway.

Metamizole (Dipyrone) hemimagnesium is an anti-inflammatory and antioxidant agent with the property of reducing body temperature. Metamizole hemimagnesium can decrease the levels of C-reactive protein (CRP) and interleukin 6 (IL-6). It is also an orally active cyclooxygenase (COX) inhibitor. Metamizole hemimagnesium can inhibit cell proliferation and promote apoptosis. It can be used in the research of inflammation and fever.

MEL23 is a MDM2 E3 ligase inhibitor that blocks the E3 ligase activity of the MDM2-MDMX complex. MEL23 inhibits Mdm2 and p53 ubiquitination in cells, reduce viability of cells with wild-type p53. MEL23 stabilizes MDM2 via a mechanism independent of p53 transcription.

MeCY5-NHS estera is a reactive dye. MeCY5-NHS estera can be used for the labeling of proteins and nucleic acids.

Mebolazine binds to the androgen receptor and produce androgenic and anabolic activity.

Me-(S,R,S)-AHPC-CO-C5-N3 is an E3 ligase ligand-linker conjugate composed of a VHL ligand and a linker . Me-(S,R,S)-AHPC-CO-C5-N3 can be used for synthesis of PROTACs, such as PROTAC CG167.

MD 780236 free base is a substrate and selective inhibitor of monoamine oxidase B (MAO-B), competitive with phenylethylamine and 5-hydroxytryptamine (5-HT).

MC-Val-Cit-PAB-Sunitinib is the conjugate of a payload Sunitinib analog. (E/Z)-Panomifene (hydrochloride) is a selective anti-estrogenic compound. (E/Z)-Panomifene (hydrochloride) has anti-tumor activity and can be used in breast cancer research.

Mc-Pro-PAB-MMAE is a Drug-Linker Conjugate for ADC. Mc-Pro-PAB-MMAE consists of Monomethyl auristatin E-induced colitis in mouse model.

Mc-PEG4-Val-Ala-PAB-Exatecan is a Drug-linker conjugate for ADC. Mc-PEG4-Val-Ala-PAB-Exatecan contains the ADC linker (Mc-PEG4-Val-Ala-PAB) and a DNA topoisomerase I inhibitor Exatecan.

MC-PEG2-VA-PAB-Exatecan (Compound DL-18) is a Drug-Linker Conjugates for ADC. MC-PEG2-VA-PAB-Exatecan consists of Exatecan-induced flinch in rats models, and exhibits anti-hyperalgesia effects in multiple pain models.

MC4762 is an inhibitor of NOX2 and MAOB, with IC50 values of 0.155 μM and 0.182 μM, respectively. MC4762 has anti-inflammatory activity, can inhibit the production of ROS, and downregulate the expression of pro-inflammatory cytokines iNOS, IL-1β, and IL-6.

MC-25B is a specific FKBP12 PROTAC degrader. MC-25B degrades FKBP12 with a DC50 of 0.35 μM and a Dmax of 89%. MC-25B facilitates the degradation of nuclear-localized FKBP12 through a DCAF16-dependent mechanism.

MBA-m1 is a MLKL inhibitor. MBA-m1 inhibits necroptosis in Mlkl−/− NIH-3T3 cells. MBA-m1 ameliorates disease in MLKL-induced dermatitis and abdominal aortic aneurysm mouse model.

Maytansine derivative M24 is an ADC Drug-Linker Conjugates for ADC that can be used to synthesize ADC REGN5093-M114.

Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of ADC toxin Calicheamicin and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADC, PF-06647263.